非奈利酮片使用时会使肌酐上升吗？

During use, fenelidone tablets may cause an increase in creatinine, which may have an impact on the patient's kidneys. Generally, the increase is mild. Patients can regularly monitor creatinine values under the guidance of a doctor.

Affects creatinine

Creatinine is a metabolite of human muscle. It is excreted from the body with urine. Usually, if creatinine is higher than the normal value, it means there is a problem with kidney function, which may cause chronic kidney disease and other diseases. If the patient finds that the creatinine index has increased after taking fenelidone, he should inform the doctor in time and handle it under the guidance of the doctor to prevent the continued increase in creatinine value from affecting his health.

Fenelidone taking time

Fenelidone needs to be taken orally, once a day. This medicine can be taken with or without food. Patients can choose the time to take the medicine according to their own conditions, before and after meals or on an empty stomach.

However, it should be noted that the medication should be taken at the same time every day to help maintain the blood concentration of the drug in the body. If the patient's stomach function is not good, it is recommended to take the medication after meals to help reduce the irritation of the drug to the stomach.

Finelidone is a selective nonsteroidal mineralocorticoid receptor antagonist that has favorable effects on cardiorenal outcomes in patients with stage 3 or 4 chronic kidney disease (CKD) who have severe albuminuria and type 2 diabetes.

In the Fenelidone Reduces Renal Failure and Disease Progression in Patients with Diabetic Nephropathy trial, Fenelidone significantly improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

One study examined whether baseline HbA1c levels and insulin treatment affected outcomes. Results: Of 5,674 patients, 3,637 (64.1%) received insulin therapy at baseline. Overall, 5,663 patients were included in the HbA1c analysis. 2 794 cases (49.3%) had a baseline HbA1c of 7.5% (58 mmol/mol). Finelidone significantly reduced the risk of the composite renal outcome independent of baseline HbA1c levels and insulin use (p-interaction 0.41 and 0.56, respectively). Fennelidone reduced the incidence of the composite cardiovascular outcome regardless of baseline HbA1c levels and insulin use (p-interaction 0.70 and 0.33, respectively).

Although baseline HbA1c levels did not affect the risk of renal events, the risk of cardiovascular events increased with increasing HbA1c levels. The decrease in UACR was consistent across subgroups. Adverse events were similar in both groups regardless of baseline HbA1c levels and insulin use. A small number of patients receiving fenelidone discontinued treatment due to hyperkalemia.

Conclusions: Fennelidone reduces the risk of renal and cardiovascular outcomes in patients with CKD and T2D, and the risk appears to be consistent regardless of HbA1c levels or insulin use.

Recommended related articles: